dbACP: A Comprehensive Database of Anti-Cancer Peptides

159 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00773 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 11.1 µMo/L
dbacp00781 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 9.7 µMo/L
dbacp00789 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 9.2 µMo/L
dbacp00797 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 8.7 µMo/L
dbacp02003 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 11.7 µg/ml
dbacp02232 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 60 µM
dbacp02242 CA-MA1 KWKLFKKIKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 100 µM
dbacp02246 CA-MA2 KWKLFKKIPKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 25 µM
dbacp02250 CA-MA3 KWKLFKKIGPGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : >100 µM
dbacp02472 Chickpea peptide ADLPGLK Plant sources Inducing apoptosis SRB assay A-549 Human endometrial cancer IC50 : 126.4 ± 1.98 µM
dbacp02627 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : 3.2 ± 0.6 µM
dbacp02748 Di-PST13-RK-C KKKFPWWWPFKKKCKKKFPWWWPFKKKC Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 17 µg/ml
dbacp02750 Di-PST13-RK-K KKKFPWWWPFKKKKKKFPWWWPFKKKK Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 15 µg/ml
dbacp02973 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 25.20 µM
dbacp02980 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 25.20 µM
dbacp02987 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 14.53 µM
dbacp02994 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 14.53 µM
dbacp03001 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 20.36 µM
dbacp03008 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 20.36 µM
dbacp03015 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 15.88 µM
dbacp03022 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 15.88 µM
dbacp03057 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 6.49 µg/ml
dbacp03570 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : > 83.6 µMo/L
dbacp03578 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : > 83.6 µMo/L
dbacp03589 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 71 µMo/L
dbacp03613 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 53 µMo/L
dbacp03621 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : >83.6 µMo/L
dbacp04486 Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay A-549 Lung cancer IC50 : 110 µM
dbacp04711 MSI-136 GIGKFLKKAKKFAKAFVKIINN African clawed frog Not specified MTT/MTS assay A-549 Lung cancer IC50 : 10 µM
dbacp04712 MSI-238 gigkflkkakkfakafvkiinn African clawed frog Not specified MTT/MTS assay A-549 Lung cancer IC50 : 6 µM
dbacp05021 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 33 µMo/L
dbacp05694 PST13-RK KKKFPWWWPFKKK Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 90 µg/ml
dbacp05706 PTP-7a FLGALFHALSKLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 28 µM
dbacp05707 PTP-7b FLGALFKALSHLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 32 µM
dbacp05708 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : >100 µg/ml
dbacp05713 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : >100 µg/ml
dbacp05718 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 13.71 µg/ml
dbacp05723 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 9.09 µg/ml
dbacp05728 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 13.94 µg/ml
dbacp05733 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 8.01 µg/ml
dbacp05738 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 24.58 µg/ml
dbacp05948 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 47.26Inhibition ratio at 50 µg/ml
dbacp05957 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 52.50 Inhibition ratio at 50 µg/ml
dbacp06169 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer Not found
dbacp06173 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : >100 µM
dbacp06253 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 45.62 inhibition ratio at 50 µg/ml
dbacp06262 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 50.64 inhibition ratio at 50 µg/ml
dbacp06349 Tritrpticin VRRFPWWWPFLRR Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : > 200 µg/ml
dbacp06748 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay A-549 Lung Cancer IC50 = 32.47 µM
dbacp06749 mPNC-NLS QETFSDLWKLLVQRKRQKLMP Synthetic p53-mediated apoptosis MTT assay A-549 Lung Cancer IC50 = 44.9 μM
dbacp06751 mPNC-NLS QETFSDLWKLLVQRKRQKLMP Synthetic p53-mediated apoptosis Cytotoxicity assay A-549 Lung Cancer IC50 = 45 μM
dbacp06768 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay A-549 Lung Cancer IC50 = 22.00 µM
dbacp06775 PMAP-NC RIIDRLWLVRRPQKPKFVLVWVL Synthetic Analgog of PMAP-24 Membrane permeabilization MTT assay A-549 Lung Cancer IC50 = 7.1 μM
dbacp06776 MP1-Q12K IDWKKLLDAAKLIL Analog of Polybia MP1 Not available MTT assay A-549 Lung Cancer IC50 = 12.5 μM
dbacp06798 Test peptide YSFGL Neuropep Peptide Not available MTT assay A-549 Lung Cancer IC50 = 26.417±0.660 µM
dbacp06859 ALA-A2 KLWCKSSQVPQSR Alpha-Lactalbumin Not available MTT assay A-549 Lung Cancer ~50% cell viability
dbacp06912 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay A-549 Lung Cancer 17.4% decrease in cell viability at 10 μM
dbacp06913 AC-P19M FAKKLAKLKKKLAKLAKKR Synthetic analogue of AC-P19 Inhibition of cell signalling WST-8 assay A-549 Lung Cancer IC50 = 9.84 µM
dbacp06915 AC-P19 FAKKLAKLKKKLAKLALAL Synthetic Inhibition of cell signalling WST-8 assay A-549 Lung Cancer IC50 = 52.14 µM
dbacp06920 HAZ GVKFAKRFWRFAKKAFKRFEK Synthetic Cell membrane destabilization MTT assay A-549 Lung Cancer IC50 = 5.44 μM
dbacp06921 Ocellatin-3N GIFDVLKNLAKGVITSLAS Leptodactylus nesiotus Not available CellTiter-Glo assay A-549 Lung Cancer LC50 = 35 ± 1 μM
dbacp06944 HTDT-6-2-3-2 GPLGAGP Enteromorpha prolifera Apoptosis inducing CCK-8 assay A-549 Lung Cancer IC50 = 0.9867 ± 0.0857 mg/mL
dbacp06979 GV1001 EARPALLTSRLRFIPK Human telomerase reverse transcriptase (hTERT) Inhibition of angiogenesis Cell Viability assay A-549 Lung Cancer Graph Fig 2A
dbacp06980 Ponericin-W1 (11-25), At1 KLLPSVVGLFKKKKQ Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 > 100 µM
dbacp06982 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKKKK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 >100 µM
dbacp06984 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKLLK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 4.3 µM
dbacp06986 At4 KLLKKLLKLLKKLLK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 7.2 µM
dbacp06988 At5 KIIKKIIKIIKKIIK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 3.6 µM
dbacp06990 At6 KVVKKVVKVVKKVVK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 > 100 µM
dbacp06992 At7 KIIKKIKKKIKKIIK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 10.3 µM
dbacp06994 At8 KLLKKLKKKLKKLLK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 13.4 µM
dbacp06996 At9 KVVKKVKKKVKKVVK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 100 µM
dbacp06998 At10 IKKIIKIIKKIIKKI Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 4.4 µM
dbacp07000 At11 IIIKKIKKKIKKIII Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 7.9 µM
dbacp07002 At12 KIIIKIKKKIKIIIK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 14.0 µM
dbacp07010 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay A-549 Lung Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07017 D-LAK-120-A kklalalakkwlalakklalalakk Synthetic ROS induction, mitochondria-mediated apoptosis. MTT assay A-549 Lung Cancer IC50 = 5.55 ± 0.13 μM
dbacp07025 [G10a]-SHa FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay A-549 Lung Cancer IC50 = 14.52 ± 1.44 µM
dbacp07032 [G10a]2-SHa FLSGIVGMLaKLFKFLKaLMFLSGIVG Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay A-549 Lung Cancer IC50 = 3.79 ± 1.61 µM
dbacp07039 [G10a]3-SHa FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay A-549 Lung Cancer IC50 = 3.74 ± 3.46 µM
dbacp07045 Jeff-[G10a]2-SHa FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay A-549 Lung Cancer IC50 = 70.71 ± 5.39 µM
dbacp07097 K2F6K2 KKFFFFFFKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 1146.23 ± 346.83 μg/mL
dbacp07098 K3F6K3 KKKFFFFFFKKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 123.10 ± 35.19 μg/mL
dbacp07099 K4F6K4 KKKKFFFFFFKKKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 62.64 ± 9.55 μg/mL
dbacp07100 K4F6K4 KKKKFFFFFFKKKK Synthetic Positive charge–driven membrane disruption apoptosis AnnexinV-FITC/PI double staining assay A-549 Lung Cancer apoptotic cells (early and late) increased from 9.59 ± 1.00% to 43.03 ± 2.13%
dbacp07101 K4F8K4 KKKKFFFFFFFFKKKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 571.87 ± 66.23 μg/mL
dbacp07116 Galaxamide (N-Me-L)L(N-Me-L)LL Galaxaura filamentosa Cell-cycle arrest induces apoptosis MTT assay A-549 Lung Cancer IC50 = 6.99 ± 0.63 µg/ml
dbacp07121 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay A-549 Lung Cancer IC50 = 4.92 ± 0.84 µg/ml
dbacp07245 CIGB-552 HARIKpTFRRlKWKYKGKFW Synthetic NF-κB inhibition enhances cisplatin synergy Sulforhodamine B assay A-549 Lung Cancer IC50 = 44.6 μM
dbacp07339 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay A-549 Lung Cancer IC50 = 4.5 µM
dbacp07362 Pal-N-Ter-TAT Pal-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Analogue of N-terminal fragment of the VDAC1 protein Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-549 Lung Cancer IC50 = 44.98 μM
dbacp07369 Piscidin 3 FIHHIFRGIVHAGRSIGRFLTG Morone chrysops x Morone saxatilis Cu²⁺-mediated membrane lipid oxidation MTT assay A-549 Lung Cancer IC50 = 21.6 µM
dbacp07370 Piscidin 3 FIHHIFRGIVHAGRSIGRFLTG Morone chrysops x Morone saxatilis Cu²⁺-mediated membrane lipid oxidation MTT assay A-549 Lung Cancer IC50 = 2.99 µM
dbacp07375 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay A-549 Lung Cancer IC50 = 2.975 µg/ml
dbacp07379 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay A-549 Lung Cancer IC50 = 15.32 µM
dbacp07383 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay A-549 Lung Cancer IC50 = 27.31 µM
dbacp07387 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay A-549 Lung Cancer IC50 = 24.01 µM
dbacp07391 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay A-549 Lung Cancer IC50 > 128 µM
dbacp07395 17BIPHE2 GBKRLVQRLKDBLRNLV Derivative of LL-37 ERK-mediated apoptosis and mitochondrial disruption MTT assay A-549 Lung Cancer IC50 = 34.33 µmol
dbacp07402 Pep GKLRLIKKLWVKKWKKKGWKA Synthetic Membrane disruption induces necrotic death MTT assay A-549 Lung Cancer IC50 = 4 µM
dbacp07438 A4K14 - Citropin 1.1 - Sp 7 GLFAVR8KKVASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 16.37 µM
dbacp07442 A4K14 - Citropin 1.1 - Sp 6 GR8FAVIKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 30.19 µM
dbacp07446 A4K14 - Citropin 1.1 - Sp 5 GLFAVIKKVAS5VIKS5L Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 9.899 µM
dbacp07450 A4K14 - Citropin 1.1 - Sp 4 GLFAVIKKS5ASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 10.51 µM
dbacp07454 A4K14 - Citropin 1.1 - Sp 3 GLFAVS5KKVS5SVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 12.11 µM
dbacp07458 A4K14 - Citropin 1.1 - Sp 2 GLFAS5IKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 12.55 µM
dbacp07462 A4K14 - Citropin 1.1 - Sp 1 GS5FAVS5KKVASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 12.48 µM
dbacp07466 Tachyplesin KWCFRVCYRGICYIRRCR Horseshoe crab Fas activation drives apoptosis/necroptosis MTT assay A-549 Lung Cancer IC50 = 35 µg/ml
dbacp07517 LL-37 Analogue 2 LKRIVQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 33.7 µg/mL
dbacp07518 LL-37 Analogue 3 AKRIVQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 29.8 µg/mL
dbacp07519 LL-37 Analogue 4 FΚRIVQRILDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 3.9 µg/mL
dbacp07520 LL-37 Analogue 5 FKSARIVQRILDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 10.7 µg/mL
dbacp07521 LL-37 Analogue 6 FKRIVQRIRDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 56 µg/mL
dbacp07522 LL-37 Analogue 7 FKRIVQRIRDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 12.5 µg/mL
dbacp07523 LL-37 Analogue 8 FKRIVQKIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 145 µg/mL
dbacp07524 LL-37 Analogue 9 FKRIVQLIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 18.9 µg/mL
dbacp07525 LL-37 Analogue 10 FKRIVQLIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 13.9 µg/mL
dbacp07526 LL-37 Analogue 11 FKRIVQRIKDLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 75 µg/mL
dbacp07527 LL-37 Analogue 12 FKRIVQRIKDLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 45.5 µg/mL
dbacp07528 LL-37 Analogue 13 FKRIVQIIKKFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 20.0 µg/mL
dbacp07529 LL-37 Analogue 14 FKRIVQIIKKFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 12.9 µg/mL
dbacp07530 LL-37 Analogue 15 FKRIVQLLKKLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 12.8 µg/mL
dbacp07531 LL-37 Analogue 16 FKRIVQLLKKLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 9.8 µg/mL
dbacp07532 LL-37 Analogue 17 FKRILQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 19.2 µg/mL
dbacp07533 LL-37 Analogue 18 FKRILQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 29.2 µg/mL
dbacp07550 NMANF2 KAIGLVIPEIDGKLDGGAQRV Staphylococcus hominis strain MANF2 GAPDH-like protein disrupts survival MTT assay A-549 Lung Cancer IC50 = 46.6 µg/mL
dbacp07860 HN-1 FALGAVTKLLPSLLCMITRKC Amolops hainanensis Apoptosis induction and immune activation MTT assay A-549 Lung Cancer Not Available
dbacp07866 R-Lycosin I derivative 8a RGWFRAMRSIARFIARERLRGHL Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I GLUT1-mediated uptake enhances cytotoxicity CCK-8 assay A-549 Lung Cancer IC50 = 9.6 ± 0.3 µM
dbacp07872 R-Lycosin I derivative 8b RGWFRAMRSIARFIARERLRGHL Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I GLUT1-mediated uptake enhances cytotoxicity CCK-8 assay A-549 Lung Cancer IC50 = 7.0 ± 0.3 µM
dbacp07889 H-58 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.62 ± 0.12 μM
dbacp07892 H-57 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.62 ± 0.12 μM
dbacp07895 H-18 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.89 ± 0.21 μM
dbacp07898 H-21 IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 3.26 ± 0.36 μM
dbacp07901 H-20 IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 2.10 ± 0.32 μM
dbacp07904 H-19 IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 1.00 ± 0.36 μM
dbacp07907 H-17 IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.96 ± 0.33 μM
dbacp07910 H-16 IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 1.85 ± 0.31 μM
dbacp07913 H-15 IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 2.26 ± 0.24 μM
dbacp07916 H-10 IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 3.59 ± 0.12 μM
dbacp07919 H-5 IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 7.35 ± 0.22 μM
dbacp07922 H-2 IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 4.26 ± 0.52 μM
dbacp07985 R-C16 RGWFRAMRSIARFIARERLREHL R-Lycosin-I Fatty-acid modification enhances peptide apoptosis CCK-8 assay A-549 Lung Cancer IC50 ~ 5 µM
dbacp08015 Ec-LDP-hBD1 MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH Synthetic EGFR-targeted defensin induces mitochondrial apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 11.9 μM
dbacp08038 Silk Fibroin peptide Not Available Silkworm Cocoons SFP induces S-phase cell-cycle arrest MTT assay A-549 Lung Cancer IC50 = 9.921 ± 0.82 mg/ml
dbacp08058 TAT-327 RKKRRQRRREFLDCFQKF Peptide-327 Peptide 327 blocks Eps8–EGFR CCK-8 assay A-549 Lung Cancer EC50 = 55.42 ± 0.84 μM
dbacp08083 Peptide 3a YD Synthetic Inhibit COX-2 enzyme MTT assay A-549 Lung Cancer IC50 = 5.7 ± 0.04 µM
dbacp08085 Peptide 3b YD Synthetic Inhibit COX-2 enzyme MTT assay A-549 Lung Cancer IC50 = 5.8 ± 0.02 µM
dbacp08088 PTP-7S EENFLGALFKALSKLL PTP-7 Not Available MTT assay A-549 Lung Cancer 65% cell viability at 10 µΜ
dbacp08178 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay A-549 Lung Cancer Not Available
dbacp08265 HR HVLSRAPR Fraction identified from Tr1 Not Available MTT assay A-549 Lung Cancer 15% inhibition at 500 μg/mL
dbacp08305 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay A-549 Lung Cancer IC50 = 36.2 μM
dbacp08307 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay A-549 Lung Cancer IC50 = 11.9 μM
dbacp08321 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay A-549 Lung Cancer Cell Viability = 1.4% at 25 μM
dbacp08334 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 A-549 Lung Cancer Cell Viability = 9.1% at 25 μM
dbacp08343 Phakellistatin 18 PIPYPIF Marine Sponge Phakellia fusca Not Available Cytotoxicity assay A-549 Lung Cancer IC50 = 72.42 µM
dbacp08345 P18-1 PIPYPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay A-549 Lung Cancer IC50 = 67.53 µM
dbacp08347 P18-2 PIPRPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay A-549 Lung Cancer IC50 = 79.71 µM
dbacp08433 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay A-549 Lung Cancer 9.4% growth inhibition at 70 μg/mL
dbacp08436 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available TUNEL assay A-549 Lung Cancer Mean apoptotic rate = 36% at 200 μg/mL